These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35677063)

  • 1. Conservative Management of Muscle Invasive Bladder Cancer in Kidney-Pancreas Transplant Patient.
    Glosser LD; Zakeri BS; Lombardi CV; Ekwenna OO
    Case Rep Transplant; 2022; 2022():5373414. PubMed ID: 35677063
    [No Abstract]   [Full Text] [Related]  

  • 2. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
    Kulkarni GS; Hermanns T; Wei Y; Bhindi B; Satkunasivam R; Athanasopoulos P; Bostrom PJ; Kuk C; Li K; Templeton AJ; Sridhar SS; van der Kwast TH; Chung P; Bristow RG; Milosevic M; Warde P; Fleshner NE; Jewett MAS; Bashir S; Zlotta AR
    J Clin Oncol; 2017 Jul; 35(20):2299-2305. PubMed ID: 28410011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trimodal therapy versus radical cystectomy for cT2N0M0 urothelial muscle-invasive bladder cancer: Single-center experience.
    Fallatah M; Alkahtani AS; Alrumayyan M; Alotaibi MF; Alkhateeb S; Mokhtar AA; Altaweel W
    Urol Ann; 2023; 15(4):406-411. PubMed ID: 38074180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bladder-sparing approaches for muscle invasive bladder cancer: a narrative review of current evidence and future perspectives.
    Fan X; He W; Huang J
    Transl Androl Urol; 2023 May; 12(5):802-808. PubMed ID: 37305635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness of Bladder-preserving Tri-modality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer.
    Royce TJ; Feldman AS; Mossanen M; Yang JC; Shipley WU; Pandharipande PV; Efstathiou JA
    Clin Genitourin Cancer; 2019 Feb; 17(1):23-31.e3. PubMed ID: 30482661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Fahmy O; Khairul-Asri MG; Schubert T; Renninger M; Malek R; Kübler H; Stenzl A; Gakis G
    Urol Oncol; 2018 Feb; 36(2):43-53. PubMed ID: 29102254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials.
    Arcangeli G; Strigari L; Arcangeli S
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):387-96. PubMed ID: 25934521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer: a propensity score matching analysis.
    Kim YJ; Byun SJ; Ahn H; Kim CS; Hong BS; Yoo S; Lee JL; Kim YS
    Oncotarget; 2017 Sep; 8(40):68996-69004. PubMed ID: 28978174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome and quality of life in octogenarian patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy or transurethral resection of the bladder tumor: a retrospective analysis of 143 patients.
    Rehme C; Fritsch B; Thomas L; Istin S; Burchert C; Hummel B; Baleanu-Curaj B; Reis H; Szarvas T; Ruebben H; Hadaschik B; Niedworok C
    Int Urol Nephrol; 2022 Jan; 54(1):71-79. PubMed ID: 34817753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bladder-sparing protocols in the treatment of muscle-invasive bladder cancer.
    Tholomier C; Souhami L; Kassouf W
    Transl Androl Urol; 2020 Dec; 9(6):2920-2937. PubMed ID: 33457265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening logs from a pilot randomized controlled trial of radical cystectomy versus chemoradiation therapy for muscle-invasive bladder cancer.
    Kaushik D; Shi Z; Liss MA; Wang H; Jha RP; Choi BY; Pruthi DK; Ha CS; Mansour AM; Svatek RS
    Urol Oncol; 2020 Jan; 38(1):4.e1-4.e6. PubMed ID: 31676280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder Cancer.
    Russell CM; Lebastchi AH; Borza T; Spratt DE; Morgan TM
    Bladder Cancer; 2016 Oct; 2(4):381-394. PubMed ID: 28035319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case report: Bladder preserving after maximal transurethral resection of the bladder tumor combined with chemotherapy and immunotherapy in recurrent muscle-invasive bladder cancer patients: A report of two cases.
    Mao J; Yang C; Xin S; Cui K; Liu Z; Wang T; Hu Z; Wang S; Liu J; Song X; Song W
    Front Med (Lausanne); 2022; 9():949567. PubMed ID: 35979208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trimodal therapy in muscle invasive bladder cancer management.
    Polo-Alonso E; Kuk C; Guruli G; Paul AK; Thalmann G; Kamat A; Solsona E; Thalmann G; Urdaneta AI; Zlotta AR; Mir MC
    Minerva Urol Nefrol; 2020 Dec; 72(6):650-662. PubMed ID: 33263367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-Surgical Bladder-Sparing Multimodal Management in Organ-Confined Urothelial Carcinoma of the Urinary Bladder: A Population-Based Analysis.
    de Angelis M; Baudo A; Siech C; Jannello LMI; Di Bello F; Goyal JA; Tian Z; Longo N; de Cobelli O; Chun FKH; Saad F; Shariat SF; Carmignani L; Gandaglia G; Moschini M; Montorsi F; Briganti A; Karakiewicz PI
    Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
    Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
    Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Clinical Complete Remission Following Neoadjuvant Pembrolizumab or Chemotherapy in Bladder-Preservation Strategy in Patients with Muscle-Invasive Bladder Cancer Declining Definitive Local Therapy.
    Chang PH; Chen HY; Chang YS; Su PJ; Huang WK; Lin CF; Hsieh JC; Wu CT
    Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of sarcopenia in bladder preservation therapy for muscle-invasive bladder cancer patients: a narrative review.
    Fukushima H; Koga F
    Transl Androl Urol; 2022 Oct; 11(10):1433-1441. PubMed ID: 36386266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy.
    Smith ZL; Christodouleas JP; Keefe SM; Malkowicz SB; Guzzo TJ
    BJU Int; 2013 Jul; 112(1):13-25. PubMed ID: 23356411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy?
    Ghandour RA; Kusin S; Wong D; Meng X; Singla N; Freifeld Y; Bagrodia A; Margulis V; Sagalowsky A; Lotan Y; Woldu SL
    Urol Oncol; 2020 Sep; 38(9):736.e11-736.e18. PubMed ID: 32684514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.